Effectiveness of an oral cholera vaccine campaign to prevent clinically-significant cholera in Odisha State, India
MetadataShow full item record
© 2015 The Authors. Background: A clinical trial conducted in India suggests that the oral cholera vaccine, Shanchol, provides 65% protection over five years against clinically-significant cholera. Although the vaccine is efficacious when tested in an experimental setting, policymakers are more likely to use this vaccine after receiving evidence demonstrating protection when delivered to communities using local health department staff, cold chain equipment, and logistics. Methods: We used a test-negative, case-control design to evaluate the effectiveness of a vaccination campaign using Shanchol and validated the results using a cohort approach that addressed disparities in healthcare seeking behavior. The campaign was conducted by the local health department using existing resources in a cholera-endemic area of Puri District, Odisha State, India. All non-pregnant residents one year of age and older were offered vaccine. Over the next two years, residents seeking care for diarrhea at one of five health facilities were asked to enroll following informed consent. Cases were patients seeking treatment for laboratory-confirmed V. cholera-associated diarrhea. Controls were patients seeking treatment for V. cholerae negative diarrhea. Results: Of 51,488 eligible residents, 31,552 individuals received one dose and 23,751 residents received two vaccine doses. We identified 44 V. cholerae O1-associated cases and 366 non V. cholerae diarrhea controls. The adjusted protective effectiveness for persons receiving two doses was 69.0% (95% CI: 14.5% to 88.8%), which is similar to the adjusted estimates obtained from the cohort approach. A statistical trend test suggested a single dose provided a modicum of protection (33%, test for trend, p = 0.0091). Conclusion: This vaccine was found to be as efficacious as the results reported from a clinical trial when administered to a rural population using local health personnel and resources. This study provides evidence that this vaccine should be widely deployed by public health departments in cholera endemic areas.
Showing items related by title, author, creator and subject.
5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: A cluster-randomised, double-blind, placebo-controlled trialBhattacharya, S.; Sur, D.; Ali, Mohammed; Kanungo, S.; You, Y.; Manna, B.; Sah, B.; Niyogi, S.; Park, J.; Sarkar, B.; Puri, M.; Kim, D.; Deen, J.; Holmgren, J.; Carbis, R.; Dhingra, M.; Donner, A.; Nair, G.; Lopez, A.; Wierzba, T.; Clemens, J. (2013)Background: Efficacy and safety of a two-dose regimen of bivalent killed whole-cell oral cholera vaccine (Shantha Biotechnics, Hyderabad, India) to 3 years is established, but long-term efficacy is not. We aimed to assess ...
Qadri, F.; Wierzba, T.; Ali, Mohammed; Chowdhury, F.; Khan, A.; Saha, A.; Khan, I.; Asaduzzaman, M.; Akter, A.; Khan, A.; Begum, Y.; Bhuiyan, T.; Khanam, F.; Chowdhury, M.; Islam, T.; Chowdhury, A.; Rahman, A.; Siddique, S.; You, Y.; Kim, D.; Siddik, A.; Saha, N.; Kabir, A.; Cravioto, A.; Desai, S.; Singh, A.; Clemens, J. (2016)Copyright © 2016 Massachusetts Medical Society. All rights reserved. Background: A single-dose regimen of the current killed oral cholera vaccines that have been prequalified by the World Health Organization would make ...
Mass Vaccination with a New, Less Expensive Oral Cholera Vaccine Using Public Health Infrastructure in India: The Odisha ModelKar, S.; Sah, B.; Patnaik, B.; Kim, Y.; Kerketta, A.; Shin, S.; Rath, S.; Ali, Mohammed; Mogasale, V.; Khuntia, H.; Bhattachan, A.; You, Y.; Puri, M.; Lopez, A.; Maskery, B.; Nair, G.; Clemens, J.; Wierzba, T. (2014)Introduction: The substantial morbidity and mortality associated with recent cholera outbreaks in Haiti and Zimbabwe, as well as with cholera endemicity in countries throughout Asia and Africa, make a compelling case for ...